drugset / Trial / NCT01855217

Pilot Study on the Pharmacodynamics of Sugammadex in Morbidly Obese Patients: Reversal of Deep Neuromuscular Blockade

NCT01855217

Phase 3 Unknown 25 enrolled St. Antonius Hospital
RandomizedParallel-groupTriple-blind

Summary

Should the dose of sugammadex in morbid obese patients be calculated on the real body weight or the ideal body weight? To study the pharmacodynamics of sugammadex in morbidly obese patients by comparing 1 mg/kg IBW versus 1 mg/kg TBW versus placebo.

Timeline

Start
2013-04
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sugammadex Other / unclassified 1 mg/kg Other

Indications

No indication recorded.